BUSINESSEconomic Times Industry ยท 2 hours agoLive
Dr Reddy's bets on generic semaglutide, biosimilars
Reported by Economic Times Industry, not nibnow. We are not the publisher of this story, only the source is.
No additional analysis available for this story yet.
WHAT HAPPENED
Dr Reddy's domestic formulations business grew in the September quarter, while Revlimid sales declined in North America. A relaunch of generic semaglutide and the US launch of abatacept biosimilar are anticipated for future growth. The company aims to sell millions of pens for semaglutide with a focus on international markets. Furthermore, an expanding biosimilars portfolio aims to strengthen its position beyond traditional generics.
Text size
READ IN YOUR LENS
UPSCMarketsFounder